Potent antagonists at the L-AP4- and (1S,3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord

doi:10.1016/S0028-3908(96)00048-2

Neuropharmacology

Volume 35, Issue 8, 1996, Pages 1029-1035

https://doi.org/10.1016/S0028-3908(96)00048-2 Get rights and content

Abstract

In this report we describe the actions of two novel compounds, (RS)-α-cyclopropyl-4-phosphonophenylglycine (CPPG) and (S)-α-ethylglutamate (EGLU), which are potent antagonists at two types of presynaptic metabotropic glutamate (mGlu) receptors in the neonatal rat spinal cord. Selective activation of these receptors by L-2-amino-4-phosphonobutyrate (L-AP4) or (lS,3S)-1-aminocyclopentane-l,3-dicarboxylic acid ((1S,3S)-ACPD) results in the depression of the monosynaptic component of the dorsal rootevoked ventral root potential (DR-VRP). CPPG produces rightward parallel shifts of the dose-response curves for both L-AP4- and (1S,3S)-ACPD, with Schild slope in each case close to unity, consistent with a competitive mechanism of antagonism. CPPG is the most potent antagonist yet described for both L-AP4- and (1S,3S)-ACPD-sensitive presynaptic mGlu receptors but displays a 30-fold selectivity for the L-AP4-sensitive receptor over the (1S,3S)-ACPD-sensitive receptor (K_D values 1.7 μM and 53 μM, respectively). EGLU, on the other hand, is selective for the (1S,3S)-ACPD-sensitive receptor, displaying little or no activity at the L-AP4-sensitive site. EGLU produces a rightward parallel shift of the dose-response curve to (1S,3S)-ACPD, with Schild slope close to unity, again indicative of a competitive mode of antagonism (K_D 66 μM). Both CPPG and EGLU displayed only weak or no antagonist activity at postsynaptic metabotropic and ionotropic glutamate receptors.

References (37)

T. Abe et al.
Molecular characterisation of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca²⁺ signal transduction
J. Biol. Chem.
(1992)
E.F. Birse et al.
Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system
Neuroscience
(1993)
M.V. Catania et al.
Metabotropic glutamate receptors are differentially regulated during development
Neuroscience
(1994)
S.A. Eaton et al.
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenyl-glycine and (itRS)-α-methyl-4-carboxyphenylglycine
Eur. J. Pharmacol. Molec. Pharmacol.
(1993)
D.E. Jane et al.
Stereospecific antagonism by (+)-α-methyl-4-carboxyphenylglycine (MCPG) of (1S,3R)-ACPD-induced effects in neonatal rat motoneurones and rat thalamic neurones
Neuropharmacology
(1993)
D.E. Jane et al.
New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord
Neuropharmacology
(1995)
P.A. Johansen et al.
Identification of 2-amino-2-methyl-4-phosphonobutanoic acid as an antagonist at the mGlu_4a receptor
Eur. J. Pharmacol. (Molec. Pharmacol. Sect.)
(1995)
M. Kemp et al.
Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors
Eur. J. Pharmacol. (Molec. Pharmacol. Sect.)
(1994)
J.M. Kinzie et al.
Distribution of metabotropic glutamate receptor 7 messenger RNA in the developing and adult rat brain
Neuroscience
(1995)
T. Knöpfel et al.
Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes
Neuropharmacology
(1995)

Y. Nakajima et al.

Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate

J. Biol. Chem.

(1993)

H. Ohishi et al.

Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat

Neuroscience

(1993)

H. Ohishi et al.

Presynaptic localization of a metabotropic glutamate receptor, mGluR7 in the primary afferent neurons: an immunohistochemical study in the rat

Neurosci. Lett.

(1995)

N. Okamoto et al.

Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction

J. Biol. Chem.

(1994)

J.-P. Pin et al.

The metabotropic glutamate receptors: structure and functions

Neuropharmacology

(1995)

P.J. Roberts

Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists — an update

Neuropharmacology

(1995)

D.D. Schoepp et al.

Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R, 4R - 4 - aminopyrrolidine - 2,4 - dcarboxytate

Neuropharmacology

(1995)

N.K. Thomas et al.

α-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists

Neuropharmacology

(1996)

Cited by (129)

Amygdala group II mGluRs mediate the inhibitory effects of systemic group II mGluR activation on behavior and spinal neurons in a rat model of arthritis pain
2019, Neuropharmacology
Citation Excerpt :
Orthosteric antagonists with high selectivity for mGluR2 and mGluR3 have been developed (Yin and Niswender, 2014). They typically block the beneficial effects of the mGluR2/3 agonists acting in a competitive mode (Jane et al., 1996; Johnson et al., 1999). In fact, intrathecal application of EGLU inhibited the antinociceptive effects of an mGluR2/3 agonist (DCG-IV) on mechanical allodynia and hyperalgesia in the spinal nerve ligation model of neuropathic pain (Zhou et al., 2011), and intraperitoneal injection of LY341495 reversed the antinociceptive behavioral effects of a group II mGluR agonist (LY379268) in the formalin pain test (Simmons et al., 2002).
The amygdala plays a critical role in emotional-affective aspects of behaviors and pain modulation. The central nucleus of amygdala (CeA) serves major output functions, and neuroplasticity in the CeA is linked to pain-related behaviors in different models. Activation of G_i/o-coupled group II metabotropic glutamate receptors (mGluRs), which consist of mGluR2 and mGluR3, can decrease neurotransmitter release and regulate synaptic plasticity. Group II mGluRs have emerged as targets for neuropsychiatric disorders and can inhibit pain-related processing and behaviors. Surprisingly, site and mechanism of antinociceptive actions of systemically applied group II mGluR agonists are not clear. Our previous work showed that group II mGluR activation in the amygdala inhibits pain-related CeA activity, but behavioral and spinal consequences remain to be determined. Here we studied the contribution of group II mGluRs in the amygdala to the antinociceptive effects of a systemically applied group II mGluR agonist (LY379268) on behavior and spinal dorsal horn neuronal activity, using the kaolin/carrageenan-induced knee joint arthritis pain model. Audible and ultrasonic vocalizations (emotional responses) and mechanical reflex thresholds were measured in adult rats with and without arthritis (5–6 h postinduction). Extracellular single-unit recordings were made from spinal dorsal horn wide dynamic range neurons of anesthetized (isoflurane) rats with and without arthritis (5–6 h postinduction). Systemic (intraperitoneal) application of a group II mGluR agonist (LY379268) decreased behaviors and activity of spinal neurons in the arthritis pain model but not under normal conditions. Stereotaxic administration of LY379268 into the CeA mimicked the effects of systemic application. Conversely, stereotaxic administration of a group II mGluR antagonist (LY341495) into the CeA reversed the effects of systemic application of LY379268 on behaviors and dorsal horn neuronal activity in arthritic rats. The data show for the first time that the amygdala is the critical site of action for the antinociceptive behavioral and spinal neuronal effects of systemically applied group II mGluR agonists.
Metabotropic glutamate receptors are involved in the detection of IMP and L-amino acids by mouse taste sensory cells
2016, Neuroscience
G-protein-coupled receptors are thought to be involved in the detection of umami and l-amino acid taste. These include the heterodimer taste receptor type 1 member 1 (T1r1) + taste receptor type 1 member 3 (T1r3), taste and brain variants of mGluR4 and mGluR1, and calcium sensors. While several studies suggest T1r1 + T1r3 is a broadly tuned l-amino acid receptor, little is known about the function of metabotropic glutamate receptors (mGluRs) in l-amino acid taste transduction. Calcium imaging of isolated taste sensory cells (TSCs) of T1r3-GFP and T1r3 knock-out (T1r3 KO) mice was performed using the ratiometric dye Fura 2 AM to investigate the role of different mGluRs in detecting various l-amino acids and inosine 5′ monophosphate (IMP). Using agonists selective for various mGluRs such as (RS)-3,5-dihydroxyphenylglycine (DHPG) (an mGluR1 agonist) and l-(+)-2-amino-4-phosphonobutyric acid (l-AP4) (an mGluR4 agonist), we evaluated TSCs to determine if they might respond to these agonists, IMP, and three l-amino acids (monopotassium l-glutamate, l-serine and l-arginine). Additionally, we used selective antagonists against different mGluRs such as (RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA) (an mGluR1 antagonist), and (RS)-α-methylserine-O-phosphate (MSOP) (an mGluR4 antagonist) to determine if they can block responses elicited by these l-amino acids and IMP. We found that l-amino acid- and IMP-responsive cells also responded to each agonist. Antagonists for mGluR4 and mGluR1 significantly blocked the responses elicited by IMP and each of the l-amino acids. Collectively, these data provide evidence for the involvement of taste and brain variants of mGluR1 and mGluR4 in l-amino acid and IMP taste responses in mice, and support the concept that multiple receptors contribute to IMP and l-amino acid taste.
Modulation of Chronic Pain by Metabotropic Glutamate Receptors
2016, Advances in Pharmacology
Metabotropic glutamate receptors (mGluRs) belong to class C G-protein-coupled receptors. They are expressed throughout the nervous system on both neurons and glial cells. In the central nervous system (CNS), mGluRs are mainly located in the proximity of the synaptic cleft where they regulate glutamatergic transmission in addition to a number of other neurotransmitters. To date, eight subtypes of mGluRs (mGluR1–mGluR8) have been cloned and classified into three groups on the basis of sequence similarities, and pharmacological and biochemical properties. Consequently, group I mGluRs includes mGluR1 and mGluR5, group II mGluRs includes mGluR2 and mGluR3, and group III mGluRs consists of mGluR4, mGluR6, mGluR7, and mGluR8. With the exception of mGluR6, whose localization is restricted within the retina, all mGluRs are ubiquitously expressed throughout the peripheral and CNS with some subtype specificity in different anatomical regions. mGluRs participate in many physiological processes and play important roles in a number of neurological conditions including anxiety, depression, schizophrenia, and neurodegenerative disorders. mGluRs also participate in the physiological transmission of pain stimuli as well as to mechanisms involved in the establishment of chronic pain. Therefore, these receptors are attractive targets for therapeutic intervention in several neurological disorders including chronic pain. Thus, understanding the physiological function and role of each mGluR subtype in the development of chronic pain will provide a better insight into the potential use of subtype-selective drugs currently being developed as orthosteric or allosteric ligands.
Progress toward advanced understanding of metabotropic glutamate receptors: Structure, signaling and therapeutic indications
2014, Cellular Signalling
Citation Excerpt :
Although currently no orthosteric agonist can completely differentiate between mGlu2 and mGlu3, an analog of LY354740 was found to exhibit mGlu2 agonist and mGlu3 antagonist activity [46], providing an opportunity to tease apart the functional effects of mGlu2 from mGlu3. EGLU is one of the first compounds that was found to antagonize mGlu2 and mGlu3 with little antagonism on group I or III mGlus [97]. LY341495 is an antagonist at mGlu2 and mGlu3 with high affinity (1.67 nM and 0.75 nM for human receptors, respectively) [99].
The metabotropic glutamate (mGlu) receptors are a group of Class C seven-transmembrane spanning/G protein-coupled receptors (7TMRs/GPCRs). These receptors are activated by glutamate, one of the standard amino acids and the major excitatory neurotransmitter. By activating G protein-dependent and non-G protein-dependent signaling pathways, mGlus modulate glutamatergic transmission both in the periphery and throughout the central nervous system. Since the discovery of the first mGlu receptor, and especially during the last decade, a great deal of progress has been made in understanding the signaling, structure, pharmacological manipulation and therapeutic indications of the 8 mGlu members.
MGlu3 receptor and astrocytes: Partners in neuroprotection
2013, Neuropharmacology
Astrocytes are currently studied intensively because of their now highlighted relevance as key players with neurons that modulate a wide range of central functions, from synaptic plasticity and synaptogenesis to regulation of metabolic and neuroinflammatory processes.
Since the discovery of mGlu3 receptors on astrocytes, accumulating evidence supports a role of these receptors not only in maintaining synaptic homeostasis and treating psychiatric disorders but also in promoting astrocyte survival in several pathologic conditions.
This review focuses on providing up-to-date knowledge regarding effects of activating astroglial mGlu3 receptors on psychiatric disorders, astrocyte and neuronal survival, and neurodegenerative diseases.
This article is part of a Special Issue entitled ‘Metabotropic Glutamate Receptors’.
Group II metabotropic glutamate receptor-mediated activation of G-proteins in rat hippocampal and striatal membranes
2013, Neuroscience Letters
Stimulation of G-proteins coupled with metabotropic glutamate receptors (mGlu receptors) was investigated by means of guanosine-5′-O-(3-[³⁵S]thio)triphosphate ([³⁵S]GTPγS) binding assay in rat hippocampal and striatal membranes. The endogenous ligand l-glutamate increased specific [³⁵S]GTPγS binding in a concentration-dependent manner with a mean EC₅₀ values of around 10 μM in both brain regions, The maximal % increase over the respective basal binding was highest in cerebral cortex, intermediate in hippocampus, and lowest in striatum. The pharmacological profiles of the responses investigated with a series of glutamatergic agonists and antagonists clearly indicated that they were mediated through group II mGlu receptors, particularly mGlu₂ subtype, in both brain regions. The pEC₅₀ and relative %E_max values for a series of agonists were essentially identical in both brain regions that were also correlated with those previously reported in cerebral cortical membranes. The selective allosteric potentiator of mGlu₂ receptor subtype, LY487379, potentiated the increasing effects of l-glutamate at a maximally effective concentration of 1 mM on specific [³⁵S]GTPγS binding, without altering the basal unstimulated binding. It is concluded that [³⁵S]GTPγS binding assay is applicable to rat hippocampal and striatal membranes to detect functional activation of Gα_i/o proteins coupled with mGlu₂ receptors.

View all citing articles on Scopus

View full text

Potent antagonists at the L-AP4- and (1S,3S)-ACPD-sensitive presynaptic metabotropic glutamate receptors in the neonatal rat spinal cord

Abstract

J. Biol. Chem.

Neuroscience

Neuroscience

Eur. J. Pharmacol. Molec. Pharmacol.

Neuropharmacology

Neuropharmacology

Eur. J. Pharmacol. (Molec. Pharmacol. Sect.)

Eur. J. Pharmacol. (Molec. Pharmacol. Sect.)

Neuroscience

Neuropharmacology

J. Biol. Chem.

Neuroscience

Neurosci. Lett.

J. Biol. Chem.

Neuropharmacology

Neuropharmacology

Neuropharmacology

Neuropharmacology